Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
Date:10/12/2008

SEATTLE, Oct. 13 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) has been selected to present at three upcoming investor conferences. The conferences include the 7th Annual BIO Investor Forum in San Francisco in October, the 19th Annual Oppenheimer & Co. Healthcare Conference, and the 9th Annual Acumen BioFin Rodman & Renshaw Healthcare Conference in November, both in New York City.

The presentations will be webcast live with slides, and available for replay after the presentation at http://www.celltherapeutics.com.

BIO Investor Forum

CTI Presentation: Thursday, October 30, 2008

8:00 AM PT/11:00 AM ET/4:00 PM CET

Room TBA, Palace Hotel, San Francisco

Oppenheimer & Co. Healthcare Conference

CTI Presentation: Monday, November 3, 2008

8:00 AM ET/2:00 PM CET/5:00 AM PT

Astor Room, Waldorf-Astoria Hotel, New York City

Acumen BioFin Rodman & Renshaw Healthcare Conference

CTI Presentation: Tuesday, November 11, 2008

10:45 AM EST/4:45 PM CET/7:45 AM PST

Kennedy I, New York Palace Hotel, New York City

Media Contact: Investors Contact:

Cell Therapeutics, Inc. Cell Therapeutics, Inc.

Dan Eramian Ed Bell

T: 206.272.4343 T: 206.272.4345

F: 206.272.4434 Lindsey Jesch Logan

E: media@ctiseattle.com T: 206.272.4347

http://www.celltherapeutics.com/press_room F: 206.272.4434

http://www.celltherapeutics.com/investors E: invest@ctiseattle.com


'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
2. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
3. Cell Therapeutics, Inc. Announces Reverse Stock Split
4. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
5. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
6. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
7. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
8. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
9. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
10. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
11. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... June 27, 2017 , ... Indiana-based Xylogenics announced ... production and fermentation process. The efficiencies created by the newest strain design ... notably the ethanol industry wherein individual production plants are planning to invest upwards ...
(Date:6/26/2017)... ... ... Two new members were elected to the University City Science Center’s Board ... J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at Temple ... Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, as ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Academy of Model ... University Aviation Association (UAA), the unifying voice for collegiate aviation education, are launching ... teamwork, competition, and success through a STEM-based education platform. , Much like the ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... designating infertility as a disease, bringing new hope for prospective parents who are ... annual meeting to back the World Health Organization’s designation in hopes of changing ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):